CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Trial volunteers receiving the highest dose of CagriSema at the end of Redefine-1 lost less body weight, about 22%, than people who got lower doses. In the new trial, dubbed Redefine-11 ...

The company's shares were up 4.2% at 1527 GMT. The CagriSema trial, called REDEFINE-1, is crucial to Novo's drug pipeline as the company loses its first mover advantage with Wegovy and Eli Lilly ...

“While the 25% weight loss was not observed in REDEFINE 1, we are encouraged by the weight loss profile of CagriSema, which stands out as one of the most substantial weight reductions observed ...